Paola Vidal-Montal

Paola Vidal-Montal

Auto-generated profile, based on publicly available information

Paola Vidal-Montal


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
JNJoan M Nolla
Joan M Nolla
CMCarmen Moragues
Carmen Moragues
LVLidia Valencia-Muntalà
Lidia Valencia-Muntalà
LBLaia de Daniel Bisbe
Laia de Daniel Bisbe
LBLaura Berbel-Arcobé
Laura Berbel-Arcobé
CGCarmen Gómez-Vaquero
Carmen Gómez-Vaquero
Background/Objectives: Rheumatoid arthritis (RA) is a chronic inflammatory disease frequently accompanied by comorbid conditions that contribute to disability and worsen long-term outcomes. Among these, malnutrition and osteosarcopenia remain under-recognised. This cross-sectional study aimed to assess the prevalence of malnutrition and osteosarcopenia among elderly women with RA and explore the clinical impact of these conditions. Methods: Sixty-five women over 65 years with RA were evaluated using Global Leadership Initiative on Malnutrition (GLIM) criteria for malnutrition and EWGSOP2-based assessments for sarcopenia; bone status was measured by dual-energy X-ray absorptiometry (DXA), trabecular bone score (TBS), and three-dimensional DXA (3D-DXA). Results: Malnutrition was identified in 49.2% and osteosarcopenia in 52.3% of participants. A significant bidirectional association was observed: malnourished patients had higher rates of osteosarcopenia (65.6% vs. 34.4%; p < 0.05), and osteosarcopenic patients were more frequently malnourished (61.8% vs. 39.1%; p < 0.05). Both conditions were associated with older age, lower body mass index (BMI), impaired muscle parameters, and reduced bone mineral density. Malnourished and osteosarcopenic patients reported worse fatigue and lower physical quality of life, despite similar inflammatory activity. Significant correlations were found between muscle mass indices and bone quality metrics assessed by 3D-DXA. These findings highlight a substantial burden of malnutrition and osteosarcopenia in elderly women with RA, even with well-controlled disease despite similar inflammatory activity (mean Disease Activity Score 28: 2.8 ± 1.0; 43.1% in remission. Conclusions: There is a substantial burden of malnutrition and osteosarcopenia in elderly women with RA that support the integration of systematic nutritional and musculoskeletal screening into routine care. Future studies should evaluate age- and disease-specific mechanisms and assess the benefit of multidisciplinary strategies to prevent frailty and improve long-term outcomes.

19 January 2025 in Lupus Science & Medicine
Verified
Journal Article
Open access
PDF file
PVPaola Vidal-Montal
Paola Vidal-Montal
FGFrancisco Javier Narvaez Garcia
Francisco Javier Narvaez Garcia
FOFrancesc Xavier Fulladosa Oliveras
Francesc Xavier Fulladosa Oliveras
FMFrancesca Mitjavila
Francesca Mitjavila
OPolga capdevila pons
olga capdevila pons
JNJoan M Nolla
Joan M Nolla
Objective: To investigate the rate and factors influencing renal relapse (RR) in proliferative lupus nephritis (LN) patients who discontinued immunosuppressive therapy (IST), as well as the long-term renal outcomes following RR. Methods: Retrospective, single-centre study of biopsy-confirmed LN patients who had received IST for at least 36 months and maintained complete renal response (CRR) for a minimum of 12 months before therapy discontinuation. Results: Of a total of 106 patients meeting the inclusion criteria, 76 with proliferative classes were selected for analysis. The median duration of IST prior to discontinuation was 83.5 months (IQR 25th–75th: 53.5–120). Relapse occurred in 29 patients (38.2%) at a median of 26.5 months (IQR 25th–75th: 9.25–63.5 months) following IST withdrawal. Relapses were classified as severe in 9 cases (31%) and moderate in 16 cases (55.2%). Renal rebiopsy was performed in 25 of these patients (86.2%), with 80% retaining the same histological class. Discontinuation of IST at ≤34 years of age significantly increased the risk of RR (adjusted HR: 3.5). In contrast, an IST duration exceeding 48 months prior to discontinuation (HR: 0.26), maintaining CRR for at least 48 months (HR: 0.32), achieving complete remission per DORIS (definition of remission in systemic lupus erythematosus) criteria at IST withdrawal (HR: 0.21) and gradual IST tapering (HR: 0.09) were associated with a reduced risk of RR. Following reintroduction of IST, 20 out of 29 patients (68.9%) achieved CRR, 5 (17.2%) achieved a partial response and 4 (13.8%) did not respond; of these, 3 patients (10.3%) progressed to end-stage renal disease. Conclusions: Successful withdrawal of IST is possible in carefully selected patients with proliferative LN. If an RR occurs, most patients are able to remain in remission after resuming IST.

27 January 2026 in Lupus Science & Medicine
Verified
Journal Article
Open access
PVPaola Vidal-Montal
Paola Vidal-Montal
AFAina Fabregat
Aina Fabregat
IAIrene Altabás-González
Irene Altabás-González
JPJosé María Pego-Reigosa
José María Pego-Reigosa
AHAndrea Hernández-Martínez
Andrea Hernández-Martínez
FGFrancisco Javier Narvaez Garcia
Francisco Javier Narvaez Garcia
Objective: To evaluate the efficacy, safety and predictive factors of belimumab (BEL)-based triple therapy in proliferative lupus nephritis (LN) in real-world settings. Methods: We conducted a multicentre, retrospective study including patients with proliferative LN (new-onset or relapsing) who initiated BEL within 6 months of a renal flare, in combination with standard-of-care. Results: 49 patients were included (mean age 37 years; 85.7% female; 67.3% Caucasian). The median time from renal flare to BEL initiation was 1 month (IQR 0–3). By 12 months, 67.3% achieved complete renal response (CRR), 75.5% primary efficacy renal response (PERR) and 83.7% at least partial renal response. Median proteinuria declined from 2.7 g/day to 0.49 g/day, with parallel improvement in estimated glomerular filtration rate (71 to 78 mL/min/1.73 m²). Patients with baseline proteinuria <3 g/day achieved significantly higher CRR (78.1% vs 47.1%; p=0.027) and PERR (84.4% vs 58.8%; p=0.048) rates. The mean glucocorticoid (GC) dose decreased from 31.7 mg/day at baseline to 3.5 mg/day at 12 months, and 26.1% of patients achieved complete GC withdrawal. Extrarenal disease activity was present in 81.6% of patients at baseline, predominantly articular and mucocutaneous, with clinically meaningful improvement in 80% during follow-up. At 12 months, 40.8% met remission by Definition Of Remission In Systemic Lupus Erythematosus (DORIS) criteria and 46.9% attained Lupus Low Disease Activity State (LLDAS). Renal treatment failure occurred in 16.3% and renal relapse in 4.1%. Adverse events were mild, and no serious BEL-related events were observed. Conclusion: BEL-based triple therapy is effective and safe in proliferative LN, achieving high renal and extrarenal response rates, substantial GC-sparing and treat-to-target outcomes in real-world practice.

22 July 2023 in Joint Bone Spine
Verified
Journal Article
Closed access
PVPaola Vidal-Montal
Paola Vidal-Montal
MTMarion Thomas
Marion Thomas
ACAlice Combier
Alice Combier
ASAlexia Steelandt
Alexia Steelandt
CMCorinne Miceli-Richard
Corinne Miceli-Richard
JAJérôme Avouac
Jérôme Avouac

31 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JNJoan M Nolla
Joan M Nolla
LVLidia Valencia-Muntalà
Lidia Valencia-Muntalà
LBLaura Berbel-Arcobé
Laura Berbel-Arcobé
DBDiego Benavent
Diego Benavent
PVPaola Vidal-Montal
Paola Vidal-Montal
CGCarmen Gómez-Vaquero
Carmen Gómez-Vaquero
Background/Objectives: Sarcopenia is now recognized as a frequent and disabling accompaniment of rheumatoid arthritis (RA), although structured screening approaches are still rarely applied in everyday practice. The SARC-F questionnaire offers a simple, validated, patient-reported tool for sarcopenia screening, but its performance in RA remains largely unexplored. We aimed to evaluate the burden of sarcopenia risk, defined by abnormal SARC-F scores (≥4), and its clinical correlates in RA compared with age- and sex-matched controls. Methods: We conducted an observational case–control study including 275 RA patients (69.5% women) aged >50 years and 300 matched controls. Clinical, laboratory, and patient-reported outcomes were recorded. Sarcopenia risk was assessed using SARC-F (cutoff ≥ 4). RA patients also underwent grip strength and gait speed testing. Multivariable regression analyses were used to identify independent correlates of abnormal SARC-F results. Results: A SARC-F score ≥ 4 was observed in 26.9% of RA patients. Compared with controls, the burden was significantly higher in women with RA (34.0% vs. 24.7%, p < 0.05) but not in men (10.7% vs. 15.0%). Within the RA cohort, abnormal SARC-F was independently associated with female sex (OR 3.14, 95% CI 1.24–7.95) and higher RAPID3 scores (OR 1.25, 95% CI 1.18–1.33). More than half of RA patients exhibited low grip strength, with partial overlap with SARC-F findings. Conclusions: The SARC-F questionnaire revealed a notable burden of sarcopenia risk in RA, particularly among women. Combined with simple grip strength testing, it offers a feasible, low-cost approach to case finding, directly applicable in routine rheumatology practice. Incorporating this strategy may enhance recognition and management of sarcopenia in RA.

19 February 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
JNJoan M Nolla
Joan M Nolla
LVLidia Valencia-Muntalà
Lidia Valencia-Muntalà
LBLaura Berbel-Arcobé
Laura Berbel-Arcobé
DBDiego Benavent
Diego Benavent
PVPaola Vidal-Montal
Paola Vidal-Montal
CGCarmen Gómez-Vaquero
Carmen Gómez-Vaquero
Background/Objectives: Nutritional risk is increasingly recognized as a relevant but under-assessed dimension of rheumatoid arthritis (RA), particularly in older adults managed in outpatient settings. Simple nutritional indices such as the Prognostic Nutritional Index (PNI) may help identify individuals at increased nutritional risk beyond conventional disease activity measures. This study aimed to characterize nutritional risk in older adults with RA using the Prognostic Nutritional Index, explore sex-specific patterns, and identify clinical associations of PNI variability, with complementary analyses focusing on high nutritional risk. Methods: We conducted an observational cross-sectional study including 275 consecutive adults aged ≥50 years with RA attending routine follow-up at a tertiary rheumatology clinic. Nutritional risk was assessed using the PNI, calculated from serum albumin and total lymphocyte count, and analyzed primarily as a continuous variable and secondarily using established cut-off values. Clinical characteristics, inflammatory markers, body mass index, laboratory parameters, and patient-reported outcomes were recorded. Analyses were stratified by sex. Multivariable linear regression models were used to identify factors associated with PNI variability, and complementary logistic regression analyses were performed to explore factors independently associated with high nutritional risk (PNI < 40). Results: More than half of the cohort (53.3%) exhibited PNI values compatible with nutritional risk. Men showed lower PNI values than women, with a markedly greater prevalence of high nutritional risk (18.0% vs. 5.0%, p < 0.001). In multivariable linear regression analyses, higher C-reactive protein levels and increasing age were independently associated with lower PNI values, whereas sex was not an independent determinant of PNI. In multivariable logistic regression analyses, increasing age and male sex were independently associated with high nutritional risk. In multivariable linear regression models restricted to men, hemoglobin emerged as the principal independent correlate of PNI. In complementary logistic regression analyses focusing on high nutritional risk (PNI < 40), hemoglobin remained the sole independent predictor (OR = 0.94, 95% CI 0.91–0.98; p < 0.01), supporting a robust association with clinically relevant nutritional risk. Conclusions: Nutritional risk assessed by the PNI is common among older adults with RA. Although sex does not independently determine PNI as a continuous measure, male sex is associated with severe nutritional risk. The PNI captures a clinically relevant dimension of disease burden that extends beyond joint inflammation and traditional activity indices, supporting its use as a pragmatic nutritional screening tool in routine rheumatology practice.